Highly Effective, Universal Influenza Vaccine

Description

This technology is a layered nanoparticle vaccine designed to be highly effective against both influenza A and B strains. In vivo testing demonstrates that the vaccine provides complete protection against both lineages of influenza B viruses with a 100% survival rate and long-lived immune responses. Notably, this vaccine also demonstrates a 100% survival rate in mice challenged with H3N2, which is the most common Influenza A virus among all age groups. With enhanced antigen uptake and long-lasting immune response, this vaccine has the potential to be a true universal influenza vaccine platform that does not require prior strain forecasting.

Influenza is a globally important cause of severe, contagious respiratory illness and a serious threat to public health and the economy. More than 3 million cases of influenza are reported in the US alone each year, resulting in high mortality and morbidity. Annual influenza infections are caused by either of two types of viruses, influenza A or influenza B. Current seasonal influenza vaccines remain suboptimal due to the need to preselect vaccine strains, antigenic drift, and time-consuming culture systems.

Benefits

Universal: Provides protection against both Influenza A and B whereas current vaccines are limited to only matched strains.
Long-Lasting Immunity: In vivo testing shows sustained antibody responses 6 months after vaccination.
Safe: No adverse effects observed during in-vivo testing. Avoids the potential risks of off-target immune responses or pre-existing immunities to nanocore carriers compared with other nanoparticle platforms.
Adaptable Platform: This layered nanoparticle vaccine provides a promising platform for continued influenza vaccine improvement including incorporation of conserved viral antigens and immune stimulators.
Better Manufacturing: No need for time-consuming chicken egg or cell culture systems and easier quality control.